These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7535942)

  • 1. Ability of linear and cyclic peptides of neutralization antigenic site 1 of poliovirus type 1 to induce virus cross-reactive and neutralizing antibodies.
    van der Werf S; Briand JP; Plaué S; Burckard J; Girard M; Van Regenmortel MH
    Res Virol; 1994; 145(6):349-59. PubMed ID: 7535942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
    Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
    Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3.
    Ferguson M; Evans DM; Magrath DI; Minor PD; Almond JW; Schild GC
    Virology; 1985 Jun; 143(2):505-15. PubMed ID: 2414909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies.
    Fiore L; Ridolfi B; Genovese D; Buttinelli G; Lucioli S; Lahm A; Ruggeri FM
    J Virol; 1997 Sep; 71(9):6905-12. PubMed ID: 9261417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.
    Blondel B; Crainic R; Fichot O; Dufraisse G; Candrea A; Diamond D; Girard M; Horaud F
    J Virol; 1986 Jan; 57(1):81-90. PubMed ID: 2416957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic structure of polioviruses of serotypes 1, 2 and 3.
    Minor PD; Ferguson M; Evans DM; Almond JW; Icenogle JP
    J Gen Virol; 1986 Jul; 67 ( Pt 7)():1283-91. PubMed ID: 2425046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice.
    Roivainen M; Montagnon B; Chalumeau H; Murray M; Wimmer E; Hovi T
    J Virol; 1990 Feb; 64(2):559-62. PubMed ID: 1688625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a T-cell epitope adjacent to neutralization antigenic site 1 of poliovirus type 1.
    Leclerc C; Deriaud E; Mimic V; van der Werf S
    J Virol; 1991 Feb; 65(2):711-8. PubMed ID: 1702841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role of neighbouring sequences on the immunogenicity of the C3 poliovirus neutralization epitope expressed at the surface of recombinant bacteria.
    van der Werf S; Charbit A; Leclerc C; Mimic V; Ronco J; Girard M; Hofnung M
    Vaccine; 1990 Jun; 8(3):269-77. PubMed ID: 1694613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immune response to poliovirus-specific synthetic peptides: effects of adjuvants and test animal species.
    Emini EA; Schleif WA; Jameson BA; Wimmer E
    J Virol Methods; 1985 Feb; 10(2):163-70. PubMed ID: 2984231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic peptides from four separate regions of the poliovirus type 1 capsid protein VP1 induce neutralizing antibodies.
    Chow M; Yabrov R; Bittle J; Hogle J; Baltimore D
    Proc Natl Acad Sci U S A; 1985 Feb; 82(3):910-4. PubMed ID: 2983321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and antigenicity of chimeric picornaviruses which express hepatitis A virus (HAV) peptide sequences: evidence for a neutralization domain near the amino terminus of VP1 of HAV.
    Lemon SM; Barclay W; Ferguson M; Murphy P; Jing L; Burke K; Wood D; Katrak K; Sangar D; Minor PD
    Virology; 1992 May; 188(1):285-95. PubMed ID: 1314456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of a monoclonal antibody and of DNA recombinant technology for the localization of a poliovirus neutralization epitope in viral capsid polypeptide VP1.
    Bruneau P; van der Werf S; Wychowski C; Siffert O; Girard M
    Dev Biol Stand; 1984; 57():177-85. PubMed ID: 6084609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis for linkage of a continuous and discontinuous neutralization epitope on the structural polypeptide VP2 of poliovirus type 1.
    Wiegers KJ; Wetz K; Dernick R
    J Virol; 1990 Mar; 64(3):1283-9. PubMed ID: 1689392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
    Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
    J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Schild GC
    Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions.
    Saikawa T; Anderson S; Momoeda M; Kajigaya S; Young NS
    J Virol; 1993 Jun; 67(6):3004-9. PubMed ID: 7684458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regions of poliovirus protein VP1 produced in Escherichia coli induce neutralizing antibodies.
    Hoatlin ME; Kew OM; Renz ME
    J Virol; 1987 May; 61(5):1442-7. PubMed ID: 3033273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene.
    Weijer K; Pfauth A; van Herwijnen R; Jarrett O; Meloen RH; Tomee C; Osterhaus AD
    Vaccine; 1993; 11(9):946-56. PubMed ID: 7692683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivity of anti-peptide and anti-poliovirus type 3 monoclonal antibodies with synthetic peptides.
    Ferguson M; Reed SE; Minor PD
    J Gen Virol; 1986 Nov; 67 ( Pt 11)():2527-31. PubMed ID: 2431104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.